Literature DB >> 33487003

Understanding and avoiding late presentation for HIV diagnosis - study protocol of a trial using mixed methods (FindHIV).

Frederik Valbert1, Eva Wolf2, Stefan Preis3, Sven Schellberg4, Knud Schewe5, Nikola Hanhoff6, Birgit Mück2, Christine Kögl2, Paul Lauscher2, Jürgen Wasem1, Silke Neusser1, Anja Neumann1.   

Abstract

Many patients infected with HIV are diagnosed at an advanced stage of illness. These late presenters are individuals with a CD4 cell count of less than 350 cells/µL and/or an AIDS defining disease at initial HIV diagnosis. Purpose of FindHIV is to develop and distribute a questionnaire/scoring system aimed at a reduction in late presentation. FindHIV uses a mixed methods approach. In a first step, primary data of patients were collected. Inclusion criteria were: age ≥ 18 years, cognitive ability and language skills to participate in the study, initial HIV diagnosis within the past 6 months, and patient informed consent. Descriptive methods and regression models are used to identify: (1) patient characteristics associated with late presentation and (2) contacts to the healthcare system with indicator diseases that did not lead to HIV testing. Secondly, a questionnaire/scoring system is created by an expert panel. Afterwards the questionnaire/scoring system is to be disseminated. The greatest challenge was in reaching an adequate sample size. Another risk may be a recall bias. Nevertheless, FindHIV is devised as an in-depth study of the phenomenon of late presentation with potential to significantly improve HIV detection.

Entities:  

Keywords:  AIDS; Germany; HIV; late presentation; mixed methods; scoring system

Mesh:

Year:  2021        PMID: 33487003     DOI: 10.1080/09540121.2021.1874276

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  1 in total

1.  [This is how I treat patients with inflammatory rheumatic diseases and HIV/AIDS with DMARDs].

Authors:  Guido Schäfer
Journal:  Z Rheumatol       Date:  2022-03-31       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.